» Articles » PMID: 33217871

Optimal Tumor Coverage with Different Beam Energies by IMRT, VMAT and TOMO: Effects on Patients with Proximal Gastric Cancer

Overview
Specialty General Medicine
Date 2020 Nov 21
PMID 33217871
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

To compare the effects of different photon energies on radiation planning by intensity-modulated radiotherapy (IMRT), volumetric-modulated arc therapy (VMAT) and helical tomotherapy (TOMO) for proximal gastric cancer (PGC). Network analysis with microarray procession and gene ontology were used to identify the effect of radiotherapy (RT) on PGC. Then, we retrospectively analyzed 8 PGC patients after receiving irradiation with a prescribed dose of 50.4 Gy. The Pinnacle treatment planning system (TPS, V9.8) was used to generate IMRT and VMAT plans by using 6 or 10 MV. TOMO plans were calculated on the Tomotherapy Planning Station Hi-Art Version 4.2.3 workstation (Tomotherapy Incorporated, Madison, WI, USA). PGC is associated with high DNA repair ability. TOMO plan results in higher tumor coverage and a better conformity index than IMRT and VMAT. 10-MV VMAT yields better dosimetric quality of the gradient index than 6-MV VMAT (P = .012). TOMO was associated with a lower irradiation dose in the mean dose to the right kidney (P = .049), left kidney and heart than 6-MV IMRT and 6-MV VMAT. 6-MV IMRT plan presented a higher dose of lung Dmean (P = .017) than 10-MV IMRT. Additionally, VMAT, using a planning energy of 6 MV, was associated with a significantly higher left kidney Dmean (P = .018) and V10 (P = .036) than a planning energy of 10 MV. TOMO is a better RT plan not only for tumor coverage but also for sparing organs at risk. IMRT and VMAT plans with 10 MV beams are more suitable than 6 MV beams for PGC treatment.

Citing Articles

Planning issues on linac-based stereotactic radiotherapy.

Huang Y, Yang J, Liu Y World J Clin Cases. 2022; 10(35):12822-12836.

PMID: 36568990 PMC: 9782937. DOI: 10.12998/wjcc.v10.i35.12822.


To Optimize Radiotherapeutic Plans for Superior Tumor Coverage Predicts Malignant Glioma Prognosis and Normal Tissue Complication Probability.

Kuo C, Liu W, Chou Y, Li M, Tsai J, Huang D J Clin Med. 2022; 11(9).

PMID: 35566538 PMC: 9099532. DOI: 10.3390/jcm11092413.


Radiotherapy for head and neck tumours using an oral fixation and parameter acquisition device and TOMO technology: a randomised controlled study.

Zhang X, Wang T, Xiao X, Li X, Wang C, Huang B BMJ Open. 2021; 11(11):e052542.

PMID: 34772753 PMC: 8593711. DOI: 10.1136/bmjopen-2021-052542.

References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

3.
Hartgrink H, van de Velde C . Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer. J Surg Oncol. 2005; 90(3):153-65. DOI: 10.1002/jso.20222. View

4.
Wang L, Yorke E, Desobry G, Chui C . Dosimetric advantage of using 6 MV over 15 MV photons in conformal therapy of lung cancer: Monte Carlo studies in patient geometries. J Appl Clin Med Phys. 2002; 3(1):51-9. PMC: 5724543. DOI: 10.1120/jacmp.v3i1.2592. View

5.
Ost P, Speleers B, De Meerleer G, De Neve W, Fonteyne V, Villeirs G . Volumetric arc therapy and intensity-modulated radiotherapy for primary prostate radiotherapy with simultaneous integrated boost to intraprostatic lesion with 6 and 18 MV: a planning comparison study. Int J Radiat Oncol Biol Phys. 2010; 79(3):920-6. DOI: 10.1016/j.ijrobp.2010.04.025. View